Normal view MARC view ISBD view

Acquired von Willebrand disease and multiple myeloma: a case report of a breast cancer survivor.

MedStar author(s):

Citation: Blood Coagul Fibrinolysis. 25(8):890-3, 2014 Dec.Blood Coagulation & Fibrinolysis. 25(8):890-3, 2014 Dec.PMID: 24911454Institution: MedStar Union Memorial HospitalDepartment: MedicineForm of publication: Journal ArticleMedline article type(s): Case Reports | Journal ArticleSubject headings: *Breast Neoplasms/bl [Blood] | *Multiple Myeloma/bl [Blood] | *von Willebrand Diseases/bl [Blood] | Antineoplastic Agents/tu [Therapeutic Use] | Breast Neoplasms/co [Complications] | Breast Neoplasms/dt [Drug Therapy] | Breast Neoplasms/pa [Pathology] | Factor VIII/me [Metabolism] | Female | Humans | Middle Aged | Multiple Myeloma/co [Complications] | Multiple Myeloma/dt [Drug Therapy] | Multiple Myeloma/pa [Pathology] | Partial Thromboplastin Time | Plasma Cells/pa [Pathology] | Survivors | Treatment Outcome | von Willebrand Diseases/dt [Drug Therapy] | von Willebrand Diseases/et [Etiology] | von Willebrand Diseases/pa [Pathology] | von Willebrand Factor/me [Metabolism]Year: 2014 Local holdings: Available online from MWHC library: June 2000 - presentISSN:

0957-5235

Name of journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosisAbstract: Acquired von Willebrand disease (aVWD) is rare disease and is associated with a variety of underlying diseases. We report a case of aVWD in the setting of multiple myeloma. The patient was a 63-year-old female with breast cancer in remission who was admitted for symptomatic anemia. She was diagnosed with multiple myeloma. She also had subcutaneous bleeding before admission. Laboratory studies revealed isolated prolongation of the activated partial thromboplastin time, which corrected in a mixing study. Her factor VIII activity, von Willebrand factor (VWF) Ag, and VWF activity were low. VWF multimer study confirmed the patient had aVWD. The treatment of aVWD is discussed in this article, including the treatment of underlying diseases, and acute management in emergent situations. An intriguing question in this case is whether the patient's multiple myeloma is a chemotherapy-induced hematological malignancy or a second primary malignancy.All authors: Jin N, Nesbitt JA, Salahuddin FFFiscal year: FY2015Digital Object Identifier:

http://dx.doi.org/10.1097/MBC.0000000000000149

Date added to catalog: 2016-07-15

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	24911454	Available		24911454

Available online from MWHC library: June 2000 - present

Acquired von Willebrand disease (aVWD) is rare disease and is associated with a variety of underlying diseases. We report a case of aVWD in the setting of multiple myeloma. The patient was a 63-year-old female with breast cancer in remission who was admitted for symptomatic anemia. She was diagnosed with multiple myeloma. She also had subcutaneous bleeding before admission. Laboratory studies revealed isolated prolongation of the activated partial thromboplastin time, which corrected in a mixing study. Her factor VIII activity, von Willebrand factor (VWF) Ag, and VWF activity were low. VWF multimer study confirmed the patient had aVWD. The treatment of aVWD is discussed in this article, including the treatment of underlying diseases, and acute management in emergent situations. An intriguing question in this case is whether the patient's multiple myeloma is a chemotherapy-induced hematological malignancy or a second primary malignancy.

English